Jefferies Financial Group Inc. Takes $28.37 Million Position in Inspire Medical Systems, Inc. $INSP

Jefferies Financial Group Inc. bought a new stake in shares of Inspire Medical Systems, Inc. (NYSE:INSP) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor bought 307,588 shares of the company’s stock, valued at approximately $28,369,000. Jefferies Financial Group Inc. owned about 1.06% of Inspire Medical Systems at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Xponance Inc. raised its position in shares of Inspire Medical Systems by 2.9% during the 3rd quarter. Xponance Inc. now owns 4,177 shares of the company’s stock valued at $310,000 after acquiring an additional 116 shares in the last quarter. Daiwa Securities Group Inc. raised its position in shares of Inspire Medical Systems by 38.7% during the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock valued at $60,000 after acquiring an additional 130 shares in the last quarter. Blair William & Co. IL raised its position in shares of Inspire Medical Systems by 5.1% during the 3rd quarter. Blair William & Co. IL now owns 4,865 shares of the company’s stock valued at $361,000 after acquiring an additional 234 shares in the last quarter. CWM LLC raised its position in shares of Inspire Medical Systems by 216.1% during the 4th quarter. CWM LLC now owns 354 shares of the company’s stock valued at $33,000 after acquiring an additional 242 shares in the last quarter. Finally, XTX Topco Ltd raised its position in shares of Inspire Medical Systems by 4.3% during the 3rd quarter. XTX Topco Ltd now owns 7,289 shares of the company’s stock valued at $541,000 after acquiring an additional 300 shares in the last quarter. 94.91% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on INSP. Bank of America lowered Inspire Medical Systems from a “neutral” rating to an “underperform” rating and set a $39.00 price target on the stock. in a research report on Friday. Royal Bank Of Canada dropped their price target on Inspire Medical Systems from $56.00 to $45.00 and set a “sector perform” rating on the stock in a research report on Tuesday, May 5th. Zacks Research lowered Inspire Medical Systems from a “hold” rating to a “strong sell” rating in a research report on Wednesday, May 13th. UBS Group set a $67.00 price target on Inspire Medical Systems in a research report on Friday, February 13th. Finally, JPMorgan Chase & Co. dropped their price target on Inspire Medical Systems from $67.00 to $54.00 and set a “neutral” rating on the stock in a research report on Tuesday, May 5th. Four investment analysts have rated the stock with a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $81.84.

Inspire Medical Systems Stock Performance

Shares of INSP opened at $43.79 on Friday. The firm has a market capitalization of $1.26 billion, a price-to-earnings ratio of 9.75, a price-to-earnings-growth ratio of 4.53 and a beta of 0.83. Inspire Medical Systems, Inc. has a one year low of $39.61 and a one year high of $147.66. The stock’s fifty day moving average is $51.61 and its 200-day moving average is $76.29.

Inspire Medical Systems (NYSE:INSP) last issued its quarterly earnings results on Monday, May 4th. The company reported $0.10 EPS for the quarter, beating analysts’ consensus estimates of ($0.28) by $0.38. The company had revenue of $204.58 million for the quarter, compared to analyst estimates of $200.04 million. Inspire Medical Systems had a return on equity of 10.35% and a net margin of 14.33%.The company’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period last year, the company earned $0.10 earnings per share. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Analysts forecast that Inspire Medical Systems, Inc. will post 0.91 EPS for the current fiscal year.

Inspire Medical Systems Profile

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.